Personalized Nanomedicine

被引:141
作者
Lammers, Twan [1 ,2 ,3 ]
Rizzo, Larissa Y. [1 ]
Storm, Gert [2 ,3 ]
Kiessling, Fabian [1 ]
机构
[1] Rhein Westfal TH Aachen, Dept Expt Mol Imaging, Aachen, Germany
[2] Univ Utrecht, Dept Pharmaceut, Utrecht, Netherlands
[3] Univ Twente, Dept Targeted Therapeut, NL-7500 AE Enschede, Netherlands
关键词
METASTATIC BREAST-CANCER; DRUG-DELIVERY; SOLID TUMORS; MEDICINE; THERAPEUTICS; DOXORUBICIN; EXPRESSION; LIPOSOMES; PET;
D O I
10.1158/1078-0432.CCR-12-1414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Personalized medicine aims to individualize chemotherapeutic interventions on the basis of ex vivo and in vivo information on patient- and disease-specific characteristics. By noninvasively visualizing how well image-guided nanomedicines-that is, submicrometer-sized drug delivery systems containing both drugs and imaging agents within a single formulation, and designed to more specifically deliver drug molecules to pathologic sites-accumulate at the target site, patients likely to respond to nanomedicine-based therapeutic interventions may be preselected. In addition, by longitudinally monitoring how well patients respond to nanomedicine-based therapeutic interventions, drug doses and treatment protocols can be individualized and optimized during follow-up. Furthermore, noninvasive imaging information on the accumulation of nanomedicine formulations in potentially endangered healthy tissues may be used to exclude patients from further treatment. Consequently, combining noninvasive imaging with tumor-targeted drug delivery seems to hold significant potential for personalizing nanomedicine-based chemotherapeutic interventions, to achieve delivery of the right drug to the right location in the right patient at the right time. Clin Cancer Res; 18(18); 4889-94. (c) 2012 AACR.
引用
收藏
页码:4889 / 4894
页数:6
相关论文
共 32 条
[1]   Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET [J].
Aerts, Hugo J. W. L. ;
Dubois, Ludwig ;
Perk, Lars ;
Vermaelen, Peter ;
van Dongen, Guus A. M. S. ;
Wouters, Bradly G. ;
Lambin, Philippe .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (01) :123-131
[2]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[3]  
[Anonymous], 2012, NAT BIOTECHNOL, V30, P1
[4]  
Chauhan VP, 2012, NAT NANOTECHNOL, V7, P383, DOI [10.1038/nnano.2012.45, 10.1038/NNANO.2012.45]
[5]   Therapeutic nanoparticles for drug delivery in cancer [J].
Cho, Kwangjae ;
Wang, Xu ;
Nie, Shuming ;
Chen, Zhuo ;
Shin, Dong M. .
CLINICAL CANCER RESEARCH, 2008, 14 (05) :1310-1316
[6]   Nanoparticle therapeutics: an emerging treatment modality for cancer [J].
Davis, Mark E. ;
Chen, Zhuo ;
Shin, Dong M. .
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (09) :771-782
[7]   Multigene Sets for Clinical Application in Glioma [J].
de Groot, John E. ;
Sulman, Erik P. ;
Aldape, Kenneth D. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (04) :449-456
[8]   Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer [J].
Dijkers, E. C. ;
Munnink, T. H. Oude ;
Kosterink, J. G. ;
Brouwers, A. H. ;
Jager, P. L. ;
de Jong, J. R. ;
van Dongen, G. A. ;
Schroder, C. P. ;
Lub-de Hooge, M. N. ;
de Vries, E. G. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) :586-592
[9]   Lab-on-a-chip: microfluidics in drug discovery [J].
Dittrich, PS ;
Manz, A .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (03) :210-218
[10]   Nanomedicine(s) under the Microscope [J].
Duncan, Ruth ;
Gaspar, Rogerio .
MOLECULAR PHARMACEUTICS, 2011, 8 (06) :2101-2141